https://ctep.cancer.gov/ | Anchor | Skip to Content A-TITLE Skip to Content |
https://ctep.cancer.gov/ | | IMG-ALT Cancer Therapy Evaluation Program (CTEP) |
/about/contactUs.htm | | IMG-ALT Contact NExT |
https://ctep.cancer.gov/ | | Home |
/sitemap.htm | | Sitemap |
/about/contactUs.htm | | Contact CTEP |
/default.htm | Text duplicate | Home |
/investigatorResources/default... | | Investigator Resources |
/investigatorResources/NCI_CTE... | | NCI CTEP IAM User Access Update |
/investigatorResources/corona_... | | Coronavirus Guidance |
/investigatorResources/biomark... | | Biomarker Resources |
/investigatorResources/career_... | | Career Development Opportunities |
/investigatorResources/childho... | | Childhood Cancer Resources |
/investigatorResources/cirb_st... | | CIRB/Study Participant Protections |
/investigatorResources/docs/Co... | New window | Conflict of Interest Policy |
/investigatorResources/funding... | | Funding Opportunities |
/investigatorResources/investi... | | Investigator’s Handbook |
/investigatorResources/radioph... | | Radiopharmaceutical Development Initiative |
/investigatorResources/default... | | Registration and Credential Repository |
/protocolDevelopment/default.htm | | Protocol Development |
/protocolDevelopment/adverse_e... | | Adverse Events/CTCAE |
/branches/pmb/agent_management... | | Agent/Drug Management |
/protocolDevelopment/amendment... | | Amendments |
/protocolDevelopment/ancillary... | | Ancillary/Correlative and Biomarker Studies |
/protocolDevelopment/cde_data_... | | CDE/Data Policies/CDUS/DMU |
/protocolDevelopment/informed_... | | Informed Consent |
/protocolDevelopment/lois_conc... | | LOIs/Concepts |
/protocolDevelopment/monitorin... | | Monitoring |
/protocolDevelopment/OEWG.htm | | OEWG Information & Timeline Reports |
/protocolDevelopment/ptmas.htm | | Project Team Member Applications |
/protocolDevelopment/default.htm | | Protocol Development Tools |
/industryCollaborations2/defau... | | Industry Collaborations |
/industryCollaborations2/agree... | | CTEP Agreements and Agents |
/industryCollaborations2/defau... | | Guidelines for Collaborations with Industry |
/initiativesPrograms/default.htm | | Initiatives / Programs |
/initiativesPrograms/etctn.htm | | Experimental Therapeutics Clinical Trials Network (ETCTN) |
/initiativesPrograms/nctn.htm | | National Clinical Trials Network (NCTN) |
/initiativesPrograms/pep-ctn.htm | | Pediatric Early Phase Clinical Trials Network (PEP-CTN) |
/initiativesPrograms/project_t... | | NCI Drug Development Project Teams |
https://nciformulary.cancer.gov/ | New window External Subdomain | The NCI Formulary |
/about/default.htm | | About CTEP |
/about/contactUs.htm | | Contact Us |
/about/directions.htm | | Map & Directions |
/about/default.htm | | Mission |
/about/org_chart.htm | | Organization Chart |
/about/staff_directory.htm | New window | Staff Directory |
/investigatorResources/NCI_CTE... | | IMG-ALT CTEP IAM and ID.me: Identity Proofing and Multi-Factor Authentication: Protecting Research Data Integrity. Learn more... |
/initiativesPrograms/nctn.htm | | IMG-ALT NCTN Overview: NCI transformed its longstanding Cooperative Group Program into the new NCI National Clinical Trials Network (NCTN) Program. |
/initiativesPrograms/etctn.htm | | IMG-ALT Experimental Therapeutics Clinical Trials Network (ETCTN) Overview: The National Cancer Institute (NCI) has formed partnerships in the pharmaceutical industr... |
https://www.cancer.gov/about-c... | New window External Subdomain | IMG-ALT NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) is a phase 2 clinical trial for children and adolescents with advanced solid tumors – includi... |
https://ctep.cancer.gov/ | Anchor | CTEP IAM Update |
https://ctep.cancer.gov/ | Anchor | NCTN |
https://ctep.cancer.gov/ | Anchor | ETCTN |
https://ctep.cancer.gov/ | Anchor | Pediatric MATCH |
/branches/oad/default.htm | | OAD |
/branches/oad/default.htm | | Office of the Associate Director |
/branches/cgcb/default.htm | | CGCB |
/branches/cgcb/default.htm | | Clinical Grants and Contracts Branch |
/branches/cib/default.htm | | CIB |
/branches/cib/default.htm | | Clinical Investigations Branch |
/branches/ctmb/default.htm | | CTMB |
/branches/ctmb/default.htm | | Clinical Trials Monitoring Branch |
/branches/pio/default.htm | | CTOIB |
/branches/pio/default.htm | | Clinical Trials Operations and Informatics Branch |
/branches/idb/default.htm | | IDB |
/branches/idb/default.htm | | Investigational Drug Branch |
/branches/pmb/default.htm | | PMB |
/branches/pmb/default.htm | | Pharmaceutical Management Branch |
/branches/rab/default.htm | | RAB |
/branches/rab/default.htm | | Regulatory Affairs Branch |
/investigatorResources/NCI_CTE... | Text duplicate | NCI CTEP IAM User Access Update |
/investigatorResources/corona_... | Text duplicate | Coronavirus Guidance |
https://www.cancer.gov/researc... | New window External Subdomain | NCI COVID-19 Research Initiatives |
https://www.cancer.gov/contact... | New window External Subdomain | About the NCI COVID-19 in Cancer Patients Study (NCCAPS) |
/initiativesPrograms/nctn.htm | | NCI’s National Clinical Trials Network (NCTN) |
/initiativesPrograms/etctn.htm | Text duplicate | Experimental Therapeutics Clinical Trials Network (ETCTN) |
/branches/cgcb/blood_and_marro... | | Blood and Marrow Clinical Trials Network (BMT CTN) |
https://navigator.ctsu.org/ | New window External Subdomain | NCTN Navigator |
/investigatorResources/childho... | | Pediatric Brain Tumor Consortium (PBTC) |
/initiativesPrograms/pep-ctn.htm | | Pediatric Early Phase-Clinical Trials Network (PEP-CTN) |
/MajorInitiatives/Pediatric_PI... | | Pediatric Preclinical in Vivo Testing (PIVOT) Program |
https://nciformulary.cancer.gov/ | New window External Subdomain Text duplicate | The NCI Formulary |
/branches/pmb/agent_management... | | Agent Management |
https://www.ctsu.org/Public/De... | New window External Subdomain | Cancer Trials Support Unit (CTSU) |
https://www.ncicirb.org/ | New window External Subdomain | Central Institutional Review Board (CIRB) |
https://ctep.cancer.gov/forms/ | | CTEP Forms, Templates and Documents |
/industryCollaborations2/agree... | | CTEP-Sponsored Agents |
/branches/pio/protocol_develop... | | Guidelines and Tools for Protocol Development and Review |
/branches/pmb/drug_training_vi... | | Investigational Drug Accountability Training |
/branches/ctmb/clinicalTrials/... | | NCI Audit Guidelines |
https://pdmr.cancer.gov/ | New window External Subdomain | NCI Patient-Derived Models Repository (PDMR) |
https://nctn-data-archive.nci.... | New window External Subdomain | NCTN/NCORP Data Archive |
/investigatorResources/default... | Text duplicate | Registration and Credential Repository |
/branches/pmb/referral_center.htm | | Special Exception (SPEX) and Treatment Referral Center (TRC) |
/DirectorsMessage/default.htm | | About the Associate Director |
/DirectorsMessage/default.htm | | More… |
/SpotlightOn/default.htm | | Research Spotlights |
/content/docs/Selected_CTEP_Ac... | New window | Selected CTEP Clinical Accomplishments – October 2024 |
https://www.cancer.gov/news-ev... | New window External Subdomain | Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma |
https://www.cancer.gov/news-ev... | New window External Subdomain | Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy |
https://governmentciomedia.com... | New window External | 50 Years of Cancer: Collaboration in Combating Childhood Cancer |
https://www.cancer.gov/news-ev... | New window External Subdomain | Seeing a Promising Future for Progress against Childhood Cancer |
https://www.cancer.gov/news-ev... | New window External Subdomain | FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL |
https://dctd.cancer.gov/NewsEv... | New window External Subdomain | Implementing Criteria to Expand Clinical Trial Eligibility — An Analysis of NCI Cancer Therapy Evaluation Program (CTEP)-Sponsored Protocols |
https://www.cancer.gov/news-ev... | New window External Subdomain | For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored |
https://www.cancer.gov/news-ev... | New window External Subdomain | Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer |
https://www.cancer.gov/news-ev... | New window External Subdomain | COVID-19 Vaccines May Be Less Effective in Some People with Cancer |
https://deainfo.nci.nih.gov/ad... | New window External Subdomain | Clinical Trials and Translational Research Advisory Committee: Strategic Planning Working Group Report, Nov. 4, 2020 |
https://www.cancer.gov/news-ev... | New window External Subdomain | Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma |
https://governmentciomedia.com... | New window External | Healthcast Podcast Featuring Drs. Jim Doroshow and Meg Mooney – 50 Years of Cancer: The Road to Better Treatment and Diagnostics |
https://www.cancer.gov/news-ev... | New window External Subdomain | Blinatumomab Improves Survival in Children with Relapsed Leukemia |
https://www.cancer.gov/news-ev... | New window External Subdomain | Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer |
https://www.cancer.gov/news-ev... | New window External Subdomain | Some Postmenopausal Women with Breast Cancer May Forgo Chemotherapy |
/MajorInitiatives/default.htm | | Other CTEP-Related Initiatives |
https://dctd.cancer.gov/NewsEv... | New window External Subdomain | NCI Announces Funding for Development of Standardized Electronic Treatment Plans for NCI-Supported Clinical Trials Applicable across Clinical Research Sites |
https://www.cancer.gov/news-ev... | New window External Subdomain | NCTN/NCORP Data Archive: Expanding Access to Clinical Trial Data |
/highlights/default.htm | | CTEP Highlights |
/branches/ctmb/clinicalTrials/... | New window | 2023 NCTN Audit Guidelines |
/branches/ctmb/clinicalTrials/... | New window | 2023 ETCTN Monitoring Guidelines |
/investigatorResources/career_... | Text duplicate | Career Development Opportunities |
/protocolDevelopment/electroni... | | CTCAE v6.0-Solicitation of Changes |
/investigatorResources/funding... | Text duplicate | Funding Opportunities |
/protocolDevelopment/docs/loi_... | New window | LOI Submission Form |
/protocolDevelopment/informed_... | | NCI Informed Consent Template |
/initiativesPrograms/nctn.htm | Text duplicate | NCTN |
/initiativesPrograms/etctn_inf... | | Updated ETCTN Guidelines |
/protocolDevelopment/docs/Prot... | New window | Protocol Status Update Form |
/MajorInitiatives/Early_Drug_D... | | Early Drug Development (EDD) Annual Meeting Schedule |
/content/docs/NCTN_Group_Meeti... | New window | NCTN Group Meeting Schedule |
https://dctd.cancer.gov/NewsEv... | New window External Subdomain | DCTD Newsletter – September 2021 |
/branches/pmb/pmb_newsroom/def... | | PMB Newsroom |
https://www.cancer.gov/researc... | New window External Subdomain | A022102, Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophage... |
https://www.cancer.gov/researc... | New window External Subdomain | EA3202, A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoi... |
https://www.cancer.gov/researc... | New window External Subdomain | NRG-GU012, Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (S... |
https://www.cancer.gov/researc... | New window External Subdomain | S2209, A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfr... |
https://www.cancer.gov/researc... | New window External Subdomain | 10605, A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Can... |
https://www.cancer.gov/researc... | New window External Subdomain | 10670, A Phase 1 Study of 5-Fluorouracil in Combination with Abemaciclib in Metastatic, Refractory CRC |
https://www.cancer.gov/researc... | New window External Subdomain | 10620, A Phase 1b Trial of Teclistamab in Combination with Iberdomide for Relapsed/Refractory Multiple Myeloma |
https://www.cancer.gov/researc... | New window External Subdomain | 10612, A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma |
/default.htm | | CTEP Home |
/about/contactUs.htm | Text duplicate | Contact CTEP |
/sitemap.htm | | Site Map |
https://www.cancer.gov/policie... | New window External Subdomain | Accessibility |
https://www.cancer.gov/policie... | New window External Subdomain | Disclaimer Policy |
https://www.cancer.gov/policie... | New window External Subdomain | FOIA |
https://www.hhs.gov/vulnerabil... | New window External Subdomain | HHS Vulnerability Disclosure |
http://www.hhs.gov/ | External Subdomain | U.S. Department of Health and Human Services |
http://www.nih.gov/ | External Subdomain | National Institutes of Health |
http://www.cancer.gov/ | External Subdomain | National Cancer Institute |
http://www.usa.gov/ | External Subdomain | USA.gov |
http://www.nih.gov/ | New window External Subdomain | No Text |
http://www.cancer.gov/ | New window External Subdomain | No Text |
http://dctd.cancer.gov/ | New window External Subdomain | No Text |
(Nice to have)